Journal Article

Bronchial artery chemoembolization with apatinib for treatment of central lung squamous cell carcinoma

Jia, Yuming, Xu, Guohui, Xu, Xiaoqian, Chen, Yaoyong, Yue, Quanji, Lei, Kaijian, Wang, Qiang, Zhu, Jun, Xiao, Guo

2022

Overview

Objective: To evaluation the clinical efficacy and safety of bronchial artery chemoembolization (BACE) combined with apatinib for treatment of advanced central lung squamous cell carcinoma (LSCC). Methods: Forty-seven patients with pathologically diagnosed stage IIIB or IV central LSCC that was not resectable were selected among hospital patients presenting after November 2016. Twenty-one patients were treated with BACE combined with apatinib; the remaining patients served as a control group treated with BACE alone. Objective response rate (ORR) and disease control rate (DCR) were evaluated with postoperative contrast-enhanced CT scans at 3, 6, and 12 months. Progression-free survival (PFS) curves were used to evaluate curative effects. Adverse events were recorded to assess safety. Results: BACE operations were successfully completed in all 47 patients. Significant differences were found at six and 12 months (P < 0.05). Median PFS was 322 days in the observation group and 209 days in the control group: a statistically significant difference (P = 0.042). One-year survival rates were 76.19% and 46.15% for observation and control patients, respectively; this difference was also significant (P = 0.037). Three patients in the observation group received emergency interventional embolization for hemoptysis, and patients with grade III or greater adverse reaction events (AE) accounted for 19.05% of patients (4/21); these subjects improved or were controlled after active treatment. Conclusion: BACE combined with apatinib is effective for treatment of advanced central LSCC, with definite short-term efficacy, controllable risk, and high safety. Investigation with a larger sample size is warranted to confirm study results.

• Publisher: Wolters Kluwer - Medknow,Medknow Publications and Media Pvt. Ltd,Medknow Publications & Media Pvt. Ltd
• Subject: Antimitotic agents / Antineoplastic agents / Arteries / Cancer / Cancer therapies / Care and treatment / Chemoembolization / Combined modality therapy / Dosage and administration / Drug therapy / Embolization / Health aspects / Hospital patients / Lung cancer / Lung cancer, Non-small cell / Methods / Oncology, Experimental / Original Article / Patient outcomes / Physiological aspects / Squamous cell carcinoma / Therapeutic chemoembolization / Therapeutic embolization / Vincristine